March 26 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BRIACELL CONTINUES CLINICAL OPERATIONS AMIDST COVID-19 PANDEMIC
* BRIACELL THERAPEUTICS - PHASE I/IIA CLINICAL STUDY OF BRIA-IMT™, WITH INCYTE'S IMMUNE CHECKPOINT INHIBITOR, INCMGA00012, IS ONGOING